GlassScriptPhysician profile
Mahazarin Behram Ginwalla
NPI 1518052877
$9,617.01
in general payments reported to CMS, 2019-2025
16 companies · $36.81 in 2025
The $36.81 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,534 · 2020: $16.32 · 2021: $1,276 · 2022: $774 · 2023: $1,699 · 2024: $281 · 2025: $36.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,611 · Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,611.00 |
| Food and Beverage | $406.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,416.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,696.43 | 2019-2023 | |
| Abbott Laboratories | $1,596.57 | 2019-2022 | |
| Pfizer INC. | $154.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $134.36 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $128.88 | 2024 | Optimizer |
| Novo Nordisk INC | $121.87 | 2024 | |
| Novartis Pharmaceuticals Corporation | $101.07 | 2019-2022 | |
| Amgen INC. | $95.10 | 2019 | |
| Daiichi Sankyo INC. | $43.17 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.42 | 2019 | |
| Scpharmaceuticals INC. | $18.42 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $18.19 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahazarin Ginwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.